Amgen Update on Patent Litigation Related to Celltrion Denosumab Biosimilar Products

Amgen Update on Patent Litigation Related to Celltrion Denosumab Biosimilar Products

We are pleased to have reached resolution of our patent infringement litigation related to Celltrion's denosumab biosimilar products. The court's order issued today (January 24, 2025), holds the claims of Amgen's U.S. patents asserted against Celltrion valid, enforceable and infringed by Celltrion's denosumab biosimilars in the United States. In addition, Amgen and Celltrion have reached a confidential settlement that allows Celltrion to launch its biosimilar products in the U.S. as early as June 1, 2025. Specific financial terms remain confidential. The settlement and court decision affirm the strength of Amgen's patent rights for denosumab.